Blink cameras can now tell you what they’re seeing with video descriptions.
The feature uses AI to give you more detailed motion notifications, like describing people the camera or doorbell detects, much like the…

Blink cameras can now tell you what they’re seeing with video descriptions.
The feature uses AI to give you more detailed motion notifications, like describing people the camera or doorbell detects, much like the…

The Palestinian Campaign for the Academic and Cultural Boycott of Israel (PACBI), a founding member of the Palestinian-led BDS movement, calls for pressure on Live Nation Entertainment, including strategic, targeted…

A Michigan man has died of rabies after receiving a kidney from another man who died of the disease when he was scratched by a skunk while defending a kitten, in what are officials are describing as an “exceptionally rare event”.
According to…

Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.
John Thys | Reuters
Pfizer on Tuesday said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharmaceutical company’s push into the weight loss space.
Pfizer will pay YaoPharma, a subsidiary of Chinese drugmaker Shanghai Fosun Pharmaceutical, an upfront payment of $150 million. YaoPharma could also receive up to $1.94 billion in milestone payments, along with tiered royalties on sales if the drug is approved.
YaoPharma’s drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk‘s blockbuster weight loss injection Wegovy. But the pill is still in early-stage development, which means it will take several years before it reaches patients.
The deal will help Pfizer beef up and diversify its obesity drug pipeline after a string of setbacks, including its decisions to scrap two different pills over the last two years. The drugmaker boosted its prospects in the competitive space with its up to $10 billion acquisition of the obesity biotech Metsera last month, following a fierce bidding war with Novo Nordisk.
“We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 small molecule which complements and strengthens our growing portfolio of novel candidates for treating obesity and its adjacent diseases,” said Chris Boshoff, Pfizer’s chief scientific officer, in a statement.
Under the terms of the agreement, YaoPharma will conduct a phase one trial on its drug, while Pfizer will take control of later development. Pfizer also plans to conduct studies combining YaoPharma’s treatment with its own drug targeting another gut hormone receptor called GIP, which is currently in mid-stage development.
That combination isn’t new in the space: Eli Lilly‘s weight loss injection Zepbound and diabetes drug Mounjaro use a dual approach of targeting both GLP-1 and GIP.
In a note on Tuesday, BMO Capital Markets analyst Evan Seigerman said limited information is available on YaoPharma’s drug, called YP05002. But Seigerman said he views “obesity diversification as promising in the short term” for Pfizer.
He added that Pfizer’s $150 million upfront payment reflects “prudent capital conservation in light of the recent Metsera bidding war.”
The opportunity to enter the booming weight loss drug market could be huge for Pfizer. Some analysts expect the weight loss drug space could be worth roughly $100 billion by the 2030s.

Tom RichardsonBBC Newsbeat
Embark StudiosA video game at the centre of a debate over artificial intelligence (AI) is in the running for the top prize at next year’s Bafta Game…

A day after Salah went public with his frustration over the lack of game time, Reds boss Slot addressed the media to offer a response, as he said: “I don’t feel that my authority has been undermined. It’s not the way I feel it. It’s not about me,…

Lateral flow tests (LFTs) are widely used across healthcare, food safety and environmental monitoring, providing rapid, on-site results. But challenges with sensitivity, flexibility and usability still limit their…

Cornell Tech faculty made a strong showing at the 2025 Conference on Neural Information Processing Systems (NeurIPS), held Dec. 2–7 in San Diego, presenting 23 research papers at one of the world’s premier gatherings for artificial intelligence and machine learning. NeurIPS draws thousands of scholars and industry leaders each year and is widely recognized as a leading forum for breakthroughs in AI, computational neuroscience, statistics, and large-scale modeling.
This year, Cornell Tech researchers pushed the boundaries of AI on multiple fronts — from safeguarding data privacy and strengthening AI evaluation standards to boosting the speed and efficiency of large language models.
Other contributions unveiled tools for analyzing environmental and health interventions, matching images to architectural plans, and generating realistic 3D scenes with unprecedented efficiency — innovations with far-reaching implications for public health, robotics, urban planning, and immersive media.
Read more on the Cornell Tech website.
